Meta Information
ID:epitalon
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-20
Model
agent_curation_2026_05_20_peptides
Interactions
Target id:
/condition/fda-compounding-risk
Target name:
FDA-Identified Compounding Safety Risk
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Epitalon is listed on the FDA's advisory of bulk drug substances for use in compounding that may present significant safety risks. It has no FDA-approved indication, no established pharmacopoeia standards, and its compounded forms lack verified purity and safety data. Any human use represents use of an unapproved drug.
Actionable advice:
Epitalon has no FDA-approved formulation and appears on the FDA compounding safety advisory. Any compounded epitalon product is unapproved with no verified quality or safety profile.
Validation status:
validated_via_regulatory
Evidence tier:
tier_b
Evidence basis:
regulatory_advisory_verbatim
Evidence anchors:
Exact phrase from label:
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Label source:
US FDA compounding advisory. Epitalon was among the 12 peptides FDA REMOVED from Category 2 on 2026-04-15; it has no FDA-approved indication and no established pharmacopoeial standard.
Action type:
informational_none
Target id:
/condition/active-cancer
Target name:
Active Cancer / Malignancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Epitalon activates telomerase, the enzyme that elongates telomeres in cells. While this mechanism is proposed to have anti-aging effects in normal cells, telomerase is also the enzyme that makes cancer cells immortal. Activating telomerase in the context of active malignancy raises a serious theoretical concern about promoting tumor survival, longevity, and resistance to therapy.
Actionable advice:
Use in patients with known cancer should be approached with extreme caution or avoided entirely, given the theoretical concern about telomerase activation potentially promoting tumor cells.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
No-data precaution: epitalon activates telomerase (a theoretical cancer concern), but there is NO human safety evidence and the previously cited paper actually showed REDUCED carcinogenesis - contradicting citation removed; precaution only.
Action type:
informational_none
Target id:
/informational/experimental-combination
Target name:
Other Experimental Anti-Aging Interventions
Severity:
moderate
Interaction type:
informational
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
No systematic drug interaction studies have been conducted for epitalon. The monograph specifically notes that concomitant use with other experimental anti-aging interventions should be carefully considered and monitored, as pharmacodynamic interactions with agents affecting telomerase, cell cycle regulation, or neuroendocrine function cannot be excluded.
Actionable advice:
If combining epitalon with other experimental anti-aging compounds, proceed with additional caution and monitoring. No safety data exist for combinations.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
No safety data exists for epitalon use during pregnancy or breastfeeding. Given the unknown effects of exogenous telomerase activation on fetal development, use must be avoided.
Actionable advice:
Epitalon should not be used during pregnancy or breastfeeding. No safety data exist.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/immunocompromised
Target name:
Immunocompromised Patients
Severity:
moderate
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The epitalon monograph notes limited safety data in immunocompromised populations. Given that immunomodulatory effects have been attributed to epithalon in preclinical models, its use in immunocompromised individuals carries uncertain risks.
Actionable advice:
This is best used with caution in immunocompromised patients. No specific safety data exist for this population.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic/precautionary: epitalon has documented immunomodulatory effects in animal models (the cited PMID 15490730 restores cellular/humoral immunity in hypophysectomized animals), but there are no human safety data, so caution in immunocompromised patients is reasonable. Animal-data-only, class-inference.
Label source:
Class inference
Action type:
informational_none
Target id:
/condition/thin-evidence-note
Target name:
Evidence Quality Notice — Highly Experimental
Severity:
unknown
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The evidentiary base for epitalon consists primarily of Russian preclinical and small clinical studies (mainly from Prof. Khavinson's group at the St. Petersburg Institute), with limited peer-reviewed replication in Western journals. No formal drug interaction studies have been conducted. All interactions listed here are based on theoretical mechanistic concerns and preclinical data. The clinical significance of any interaction is genuinely unknown.
Actionable advice:
Approach epitalon with appropriate skepticism regarding evidence quality. No formal human pharmacokinetic, safety, or drug interaction studies have been conducted by independent groups.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is unknown if Epitalon or its metabolites are excreted in breast milk or what their potential effects on a nursing infant might be.
Actionable advice:
It should be avoided completely while breastfeeding due to unknown risks to the infant.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/procedure/oral-administration
Target name:
Oral Administration (Swallowing)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
As a peptide, Epitalon is rapidly degraded by digestive enzymes in the gastrointestinal tract, which breaks it down and prevents any systemic absorption or effect.
Actionable advice:
Epitalon should never be taken orally; it must be administered via injection or a properly formulated nasal spray to be effective.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/class/immunosuppressants
Target name:
Immunosuppressant Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Epitalon has been shown to modulate the immune system, particularly T-cell function. This immunostimulatory effect could theoretically counteract the intended action of immunosuppressive drugs.
Actionable advice:
Epitalon is best avoided when taking immunosuppressants for an autoimmune condition or organ transplant.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/class/estrogens
Target name:
Estrogens and Progestins (Hormonal Therapy & Contraceptives)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Some research suggests Epitalon can influence the hypothalamic-pituitary-gonadal axis, potentially altering levels of gonadotropins (LH, FSH) and interfering with the efficacy of hormonal therapies.
Actionable advice:
It is important to consult a healthcare provider before use, as it may theoretically alter the effects of hormonal medications.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/intervention/dasatinib-quercetin
Target name:
Senolytics (Dasatinib + Quercetin)
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Epitalon's primary mechanism of activating telomerase promotes cell survival and longevity, which is mechanistically opposite to the goal of senolytics, which is to clear senescent (aged) cells.
Actionable advice:
Epitalon is best not used concurrently with senolytic therapy cycles, to avoid opposing biological signals.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
null
Description:
Epitalon is believed to regulate pineal gland function and normalize melatonin rhythms. Administering it before sleep aligns with the body's natural circadian cycle for melatonin production.
Actionable advice:
Administer the dose approximately 1 hour before your intended bedtime for optimal effect.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
separate
Target id:
/intervention/melatonin
Target name:
Melatonin
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Since Epitalon may normalize the body's own melatonin production, taking additional melatonin could lead to excessive drowsiness or potentially disrupt the natural rhythm Epitalon aims to restore.
Actionable advice:
This is best used with caution; reducing or pausing exogenous melatonin while on an Epitalon cycle may help.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/class/bioactive-peptides
Target name:
Other Bioactive Peptides
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The safety and pharmacological interactions of combining multiple research peptides are largely unknown. Concurrent use could lead to unpredictable synergistic, additive, or antagonistic effects.
Actionable advice:
Other peptides (e.g., BPC-157, TB-500) are generally best avoided unless under expert medical supervision, due to a lack of safety data.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/class/live-vaccines
Target name:
Live Attenuated Vaccines
Severity:
minor
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
72
Hours after target:
336
Description:
Because Epitalon may modulate immune system activity, it could theoretically alter the body's intended immunological response to a live attenuated vaccine.
Actionable advice:
As a precaution, avoid using Epitalon for at least 3 days before and 2 weeks after receiving a live vaccine.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid